

## EXHIBIT A

### Claim Amendments: Pending Claims

1. An ApoA-I agonist compound comprising:

(i) a 15 to 26- residue peptide or peptide analogue according to formula (I) which forms an amphipathic  $\alpha$ -helix in the presence of lipids and exhibits at least about 38% LCAT activation activity as compared with human ApoA-I wherein one or two helical turns are deleted from formula (I), wherein a helical turn consists of 3 to 4 consecutive residues selected from residues  $X_1$  to  $X_{23}$  of formula (I):

$Z_1-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-X_{18}-X_{19}-X_{20}-X_{21}-X_{22}-X_{23}-Z_2$

or a pharmaceutically acceptable salt thereof, wherein:

- $X_1$  is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p);
- $X_2$  is an aliphatic residue;
- $X_3$  is a Leu (L) or Phe (F);
- $X_4$  is Glu (E)
- $X_5$  is an aliphatic residue;
- $X_6$  is Leu (L) or Phe (F);
- $X_7$  is Glu (E) or Leu (L);
- $X_8$  is Asn (N) or Gln (Q);
- $X_9$  is Leu (L);
- $X_{10}$  is Leu (L), Trp (W) or Gly (G);
- $X_{11}$  is an acidic residue;
- $X_{12}$  is Arg (R);
- $X_{13}$  is Leu (L) or Gly (G);
- $X_{14}$  is Leu (L), Phe (F) or Gly (G);
- $X_{15}$  is Asp (D);
- $X_{16}$  is Ala (A);
- $X_{17}$  is Leu (L);
- $X_{18}$  is Asn (N) or Gln (Q);
- $X_{19}$  is a basic residue;
- $X_{20}$  is a basic residue;
- $X_{21}$  is Leu (L);

- X<sub>21</sub> is Leu (L);
- X<sub>22</sub> is a basic residue;
- X<sub>23</sub> is absent or a basic residue;
- Z<sub>1</sub> is H<sub>2</sub>N- ;
- Z<sub>2</sub> is -C (O) NRR or -C (O) OR;

each R is independently -H, (C<sub>1</sub>-C<sub>6</sub>) alkyl, (C<sub>1</sub>-C<sub>6</sub>) alkenyl, (C<sub>1</sub>-C<sub>6</sub>) alkynyl, (C<sub>5</sub>-C<sub>20</sub>) aryl, (C<sub>6</sub>-C<sub>26</sub>) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one more bonds between residues 1-7 are independently a substituted amide, an isostere of an amide or an amide mimetic; and

each "-" between residues X<sub>1</sub> to X<sub>23</sub> and between residues of the peptide to Z<sub>2</sub> independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic; or

an N- terminally blocked form, a C-terminally blocked form, or an N- and C-terminally blocked form of formula (I).

- 56. The 15 to 26-residue peptide or deleted peptide analogue of Claim 1, in which one helical turn is deleted.
- 57. The 15 to 26-residue peptide or peptide analogue of Claim 1, in which three, four, six, seven or eight residues X<sub>1</sub> , X<sub>2</sub> , X<sub>3</sub> , X<sub>4</sub> , X<sub>5</sub> , X<sub>6</sub> , X<sub>7</sub> , X<sub>8</sub> , X<sub>9</sub> , X<sub>10</sub> , X<sub>11</sub> , X<sub>12</sub> , X<sub>13</sub> , X<sub>14</sub> , X<sub>15</sub> , X<sub>16</sub> , X<sub>17</sub> , X<sub>18</sub> , X<sub>19</sub> , X<sub>20</sub> , X<sub>21</sub> and X<sub>22</sub> are deleted.
- 58. The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 3 consecutive residues are deleted.
- 59. The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 4 consecutive residues are deleted.
- 60. The 15 to 26-residue peptide or peptide analogue of Claim 57, in which two non-contiguous sets of 3 consecutive residues are deleted.
- 61. The 15 to 26-residue peptide or peptide analogue of Claim 57, in which two non-contiguous sets of 4 consecutive residues are deleted.

62. The 15 to 26-residue peptide or peptide analogue of Claim 57, in which one set of 3 consecutive residues and one set of 4 consecutive residues are deleted.
63. The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 6, 7 or 8 consecutive residues are deleted.
67. The 15 to 26-residue peptide or peptide analogue of Claim 1 in which:  
the "-" between residues designates -C (O) NH- ;  
Z<sub>1</sub> is H<sub>2</sub>N- ; and  
Z<sub>2</sub> is -C (O) OH or a salt thereof.
68. The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobic moment,  $\langle \mu_H \rangle$ , is 0.45 to 0.65.
69. The 15 to 26-residue peptide or peptide analogue of Claim 68, in which the mean hydrophobic moment,  $\langle \mu_H \rangle$ , is 0.50 to 0.60.
70. The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity,  $\langle H_o \rangle$ , is -0.050 to -0.070.
71. The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity,  $\langle H_o \rangle$ , is -0.030 to -0.055.
72. The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity of the hydrophobic face,  $\langle H_o^{pho} \rangle$ , is 0.90 to 1.20.
73. The 15 to 26-residue peptide or peptide analogue of Claim 72, in which the mean hydrophobicity of the hydrophobic face,  $\langle H_o^{pho} \rangle$ , is 0.94 to 1.10.
74. The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the pho angle is 160° to 220°.
75. The 15 to 26-residue peptide or peptide analogue of Claim 74, in which the pho angle is 180° to 200°.
79. A pharmaceutical composition comprising an ApoA-I agonist compound and a pharmaceutically acceptable carrier, excipient or diluent, wherein the ApoA-I agonist

compound is a 15 to 26-residue peptide or peptide analogue according to Claim 1 or 57.

82. The pharmaceutical composition of Claim 79 which is a lyophilized powder.
83. The pharmaceutical composition of Claim 79 which is a solution.
84. The N-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.
85. The 15 to 26-residue peptide or peptide analogue of Claim 84 in which the N-terminally blocking group is selected from the group consisting of acetyl, formyl and dansyl.
86. The C-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.
87. The 15 to 26-residue peptide or peptide analogue of Claim 86 in which the C-terminally blocking group is methyl.
88. The N-terminally and C-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.